Bristol Myers joins the lab rush in Cambridge with plans to consolidate R&D ops in a biotech campus now under construction
Bristol Myers Squibb is following Sanofi on the big trek to a new biotech campus now being built in the booming Cambridge, MA biopharma R&D hub.
The pharma giant has inked a 360,000-square-foot lease at Cambridge Crossing, where the dirt is flying on a sprawling 43-acre life sciences hub on the city line between Cambridge and Somerville.
Bristol Myers plans to consolidate its staff in the area, which includes a location at 100 Binney Street, with plans to move into a new building at 250 Water Street in 2023.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,500+ biopharma pros reading Endpoints daily — and it's free.